Esophageal Carcinoma
Conditions
Keywords
Esophageal Carcinoma, chemoradiation, radiation dose
Brief summary
Radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with localized carcinoma of the esophagus selected for nonsurgical treatment. The standard radiation dose is 50-50.4Gy/1.8-2.0Gy/F.All of this were based on 2D radiation technology. Entering new century, 3D-CRT or IMRT has used on esophageal cancer. In China,the recommend radiation dose of concurrent chemoradiation was 60Gy. The study is a clinical phase III, randomized trial to compare the different radiation dose(60Gy vs 50Gy) of concurrent chemoradiation using 3D-CRT or IMRT in patients with unresectable esophageal carcinoma.
Interventions
RADIATIONintensity modulated radiation therapy in both arms
DRUGconcurrent chemotherapy with radiation
docetaxel plus cisplatin were used weekly in both arms
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histological or cytologic diagnosis of esophageal carcinoma * ECOG performance status 0-1 * Age:18-70 years * Joined the study voluntarily and signed informed consent form * Patients must not have received any prior anticancer therapy * Unresectable disease, or refuse surgery.Stage Ⅰ-ⅣA（AJCC 2009） * Target lesions can be measured according to RECIST criteria * No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL\<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN * Use of an effective contraceptive for adults to prevent pregnancy * Life expectancy of more than 3 months
Exclusion criteria
* Multiple carcinomas of the esophagus, * Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula, * Metastatic disease (M1), * A primary tumor that extended to within 2 cm of the gastroesophageal junction, * Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor, * Concurrent pregnancy or lactation, history of a second malignancy other than nonmelanoma skin cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 5 years |
Other
| Measure | Time frame |
|---|---|
| local control rate; relapse location; toxicity | 5 years |
| radiation-related advent events | at least 3 years |
Countries
China
Contacts
Primary Contactxiao zheng, MD
Backup Contactming chen, PHD
Outcome results
None listed